News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Advertisement

Martina Porter, MD

Advertisement

Articles by Martina Porter, MD

3 Things You Should Know About HS Pathology and Management

ByPER Editorial Staff,Raj Chovatiya, MD, PhD, MSCI,Jason E. Hawkes, MD, MS,Martina Porter, MD
May 1st 2024

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Advertisement

Latest Updated Articles

  • 3 Things You Should Know About HS Pathology and Management
    3 Things You Should Know About HS Pathology and Management

    Published: May 1st 2024 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

2

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

3

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

4

Dermatology Conferences and Meetings Calendar: December 2025

5

ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us